Australia markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
4.5500-0.0300 (-0.66%)
At close: 04:00PM EST
4.5000 -0.05 (-1.10%)
After hours: 04:59PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 14.21M
Enterprise value 7.01M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)6.13
Price/book (mrq)2.57
Enterprise value/revenue 3.38
Enterprise value/EBITDA -0.92

Trading information

Stock price history

Beta (5Y monthly) 0.26
52-week change 3-29.78%
S&P500 52-week change 3-7.75%
52-week high 316.8000
52-week low 31.3720
50-day moving average 32.7466
200-day moving average 32.8275

Share statistics

Avg vol (3-month) 341.06k
Avg vol (10-day) 383.82k
Shares outstanding 53.34M
Implied shares outstanding 6N/A
Float 82.35M
% held by insiders 12.46%
% held by institutions 11.87%
Shares short (12 Jan 2023) 436.33k
Short ratio (12 Jan 2023) 41.08
Short % of float (12 Jan 2023) 41.11%
Short % of shares outstanding (12 Jan 2023) 41.09%
Shares short (prior month 14 Dec 2022) 438.64k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 322 May 2022

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)-367.79%

Management effectiveness

Return on assets (ttm)-38.03%
Return on equity (ttm)-157.06%

Income statement

Revenue (ttm)2.07M
Revenue per share (ttm)0.69
Quarterly revenue growth (yoy)-10.60%
Gross profit (ttm)1.29M
Net income avi to common (ttm)-8.09M
Diluted EPS (ttm)-2.9850
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)12.35M
Total cash per share (mrq)3.69
Total debt (mrq)5.15M
Total debt/equity (mrq)93.15
Current ratio (mrq)7.06
Book value per share (mrq)1.65

Cash flow statement

Operating cash flow (ttm)-6.09M
Levered free cash flow (ttm)-3.57M